Congress Program

Preliminary Program Subject to change

Monday, 15 October

08:00-16:30

Registration

08:30-08:35

Congress Opening and Welcome from Congress Chair
Thomas Wilckens, 
InnVentis Ltd., Israel

08:35-10:30

Session I: Rare Diseases an Avenue to #Precision Medicine
Session Chair: Catherine Brownstein, Harvard, USA

08:35-09:00

Genomics, Precision Medicine, and Rare Diseases at Boston Children’s Hospital
Catherine BrownsteinHarvard, USA

09:00-09:25

Improving Rare Disease Diagnosis with Metabolomics
John Ryals, Metabolon Inc, USA

09:25-09:50

Precise and Agile Biomarker Approaches in Pharmaceutical R&D. How to Avoid Ending up with a Stamp Collection?
Peter GroenenIdorsia, Switzerland

09:50-10:15

Towards Precision Medicine in Understudied Global Populations – The Qatar Experience
Khalid A. Fakhro, 
Sidra Medicine, Qatar

10:15-10:35

Deciphering Autoimmunity & Inflammation with Multi-omics & AI
Thomas WilckensInnVentis Ltd., Israel

10:35-11:00

Coffee & Networking Break

11:00-12:30

Session II: Moving Forward in Chronic Diseases
Session Chair: Christof Wascher, Microsoft, Switzerland

11:00-11:20

Towards a Systems Approach for Chronic Diseases, with More Agility
Michael RebhanNovartis, Switzerland

11:20-11:40

The PRECISESADS Project: Towards the Reclassification of the Systemic Autoimmune Diseases
Marta Alarcón RiquelmeGenyo, Spain

  • Diagnosis of autoimmune diseases is delayed and leads to bad therapeutic responses because it uses clinical criteria instead of molecular pathways.
  • We aim at molecularly reclassify systemic autoimmune diseases
  • The integration of high level transcriptome/methylome data leads to a new disease classification where the clinical diagnoses do not match the molecular groups.

11:40-12:00

Precision Medicine @Microsoft Focus on Immunity Mapping
Christof WascherMicrosoft, Switzerland

12:00-12:20

Alzheimer’s Disease: From Differential Diagnosis to Precision Medicine
Maria Teresa Ferretti, University of Zurich, Switzerland

12:20-12:30

Discussion

12:30-13:30

Lunch & Networking Break

13:30-15:10

Session III: Artificial Intelligence, the Enabler of Precision Medicine
Session Chair: Richard Barker, New Medicine Partners, UK

13:30-13:50

AI in Healthcare: Implementation Strategies and Enterprise Valuation
Justus Wolff, Syte, UK

13:50-14:10

Next Generation Data Science in Precision Medicine: A Roadmap to Create Insight and Avoid Data Deluge
Alexander Manta, InnVentis Ltd
., Israel

14:10-14:30

Predicting Personal Immune Scenarios
Enkelejda Miho, FHNW Switzerland, Switzerland

14:30-14:50

Deep Learning in Life Sciences: Successes, Methods, and Applications
Kristina Preuer, Johannes Kepler University Linz, Austria

14:50-15:10

The End of Medicine as we Know it
Harald Schmid, Maastricht University, The Netherlands

15:10-15:35

Coffee & Networking Break

15:35-17:25

Session IV: Artificial Intelligence in #Precision Medicine: Applications & Challenges
Session Chair: Harald Schmid, Maastricht University, The Netherlands

15:35-16:00

Evidence Synthesis -- A New Frontier for Machine Learning/AI (Back to the Future)
Athula HerathNovartis, UK

16:00-16:25

Using AI and Real-World Evidence to Take the “Trial and Error” out of Prescribing
Dekel TaliazTaliaz Ltd., Israel

16:25-16:50

Real World Medicine and Real World Patients: Critical Understanding for Translational and Precision Medicine
Michael LiebmannIQ Analytics, USA

16:50-17:15

Systems Medicine - or - What I Learned About Arnold Schwarzenegger While Studying Breast Cancer Survival
Jan Baumbach, Technical University of Munich, Germany

17:15-17:25

Discussion

17:25

End of Day One


Tuesday, 16 October

08:00-16:30

Registration 

08:40-10:30

Session V: Omics as Drivers of Innovation
Session Chair: Mark PunyanityaPhenoMx Inc., USA

08:40-09:05

The Ultimate Quantified Self: A Digital Physical Examination for Precision Medicine
Mark Punyanitya
PhenoMx Inc., USA

09:05-09:30

Combining Radiological, Clinical and Genomic Data: The Future of Data Driven Medicine in Oncology
Thierry ColinSOPHiA GENETICS, France

09:30-09:55

Liquid Biopsies’ Potential Beyond Cancer 
Simon LucasMerck KGaA, Germany

09:55-10:20

Precision Metabolomics™
Nicolas SchauerMetabolon Inc., USA

10:20-10:30

Discussion

10:30-11:00

Coffee & Networking Break

11:00-12:30

Session VI: Precision Medicine for Infectious Diseases  
Session Chair: Achim PlumCuretis N.V., Germany

11:00-11:25

Precise Instead of Broad-Spectrum: The Coming Wave of Biological Antibiotics
Alexander Belcredi, PhagoMed Biopharma GmbH, Austria

11:25-11:50

Precision Medicine for Microbial Infections and Antibiotic Resistance – BioIT Battling Bad Bugs
Achim Plum
Curetis N.V., Germany

11:50-12:15

Deciphering Human Infection Resistance with Machine Learning: A Way to Novel Antibiotics?
Krishnaveni Vijayanandbiotx.ai GmbH, Germany

12:15-12:30

Discussion

12:30-13:30

Lunch & Networking Break

13:30-15:00

Session VII: Next Generation Clinical Trials
Session Chair: Daniel Bock, Life Science/Pharma R&D, Germany

13:30-13:55

Next generation clinical trials in chronic inflammatory/autoimmune diseases: Ideas and challenges
Dennis Lauth, Lauth - Strat2Ex BioPharma Consulting, Germany

13:55-14:20

Next Generation Clinical Research
Armin Furtwängler,
 Boehringer Ingelheim, Germany

14:20-14:45

Will IoHT Provide the Key to Precision Medicine?
Marie Mc Carthy,
 ICON plc, Ireland

14:45-15:00

Discussion

15:00-15:30

Coffee & Networking Break

15:30-17:00

Session VIII: Financing Disruption
Session Chair: Horst Domdey, Bio-M, Germany

15:30-15:45

Agile, Collaborative & Open: New Ways to Shape Health Innovation
Thomas Brenzikofer,
 DayOne, Switzerland

  • What is health innovation: from doing things better to doing things different
  • Why collaboration is the key success factor in health innovation
  • The building blocks of an innovation hub

15:45-16:00

De-Risking Early Stage Science Ventures 
Pierre-Louis Joffrin, 
Deep Science Ventures, UK

16:00-17:00

Panel Discussion:

Thomas Brenzikofer, DayOne, Switzerland

Pierre-Louis Joffrin, Deep Science Ventures, UK

Ajit Singh, Artiman Ventures, USA 

Patrick Pfeffer, aescuvest International, Germany

Axel Polack, Joint Polish Investment Fund, Germany

17:00

End of Congress